Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rezolute (RZLT) Change in Interest Receivables (2012 - 2014)

Rezolute recorded quarterly Change in Interest Receivables of -$1.0 in Q2 2014, down 100.03% quarter-over-quarter from $3379.0 in Q1 2014, and down 100.03% year-over-year from $3341.0 in Q2 2013.

Rezolute's Change in Interest Receivables history runs 3 years deep, the most recent figure standing at -$1.0 for Q2 2014.

  • In Q2 2014, Change in Interest Receivables fell 100.03% year-over-year to -$1.0; the TTM figure through Mar 2015 stood at -$1.0 (down 100.01% YoY), while the FY2014 annual figure was $10211.0, up 136.2% from the prior year.
  • Change in Interest Receivables came in at -$1.0 for Q2 2014 at Rezolute, down from $3379.0 in the prior quarter.
  • In the past five years, Change in Interest Receivables ranged from a high of $24436.0 in Q2 2012 to a low of -$30824.0 in Q1 2013.
  • A 3-year average of $2967.0 and a median of $3379.0 in 2013 frame the typical range for Change in Interest Receivables.
  • Across the five-year window, Change in Interest Receivables tumbled 286.0% in 2013 and surged 110.96% in 2014, its largest moves.
  • Rezolute's Change in Interest Receivables stood at $24436.0 in 2012, then plunged by 86.17% to $3379.0 in 2013, then tumbled by 100.03% to -$1.0 in 2014.
  • According to Business Quant data, Change in Interest Receivables over the past three periods registered -$1.0, $3379.0, and $3379.0 for Q2 2014, Q1 2014, and Q4 2013 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Interest Receivables (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Rezolute 374.41 Mn 374.41 Mn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2014 -1.00
Mar 31, 2014 3,379.00
Dec 31, 2013 3,379.00
Sep 30, 2013 3,454.00
Jun 30, 2013 3,341.00
Mar 31, 2013 -30,824.00
Jun 30, 2012 24,436.00
Mar 31, 2012 16,572.00